Dude, I keep throwing up papers and data to tackle the baseless opinions others make on RCE's shortcomings on . You are now wondering onto past applications of RCE that are irrelevant to that debate and this thread, that are no doubt very fair criticisms of RCE management. There's been a lot of baseless rubbishing of RCE's results on this specific trial that I simply responded to with refuting data.
Again your early observations on the sparseness of the data entirely agreed with. I presume RCE will eventually reveal the Lipsky composite scores - and that neither the Chair or CMO said as much under interview or release a bit crap. Feel free to ask the company to reveal them and I will join you.
You said "absolutely no data" (now you;ve changed your tune). If it quacks likes a doughnut, it probably is a doughnut. Anyone with a modicum of intelligence agreed the simple data was not enough. Again, if you hold, get onto investor relations. I will.
RCE Price at posting:
43.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)